I sold this stock way too soon, out of fear. Worst mistake I made in 2007. But I'm not a bio-tech investor. Congrats to those who held. Here is an old post of mine which makes reference to a US patent that was granted back in 1991, for an appendicitis *urine* test. That test appears to have been every bit as accurate as the APPY-score test.
I still don't know why that urine test was never commercialized, when the medical community is supposedly dying for just such a test. It didn't add up in my head. But I am not an expert in this field by any means. And bio-tech stocks are definitely not my forte. I'd appreciate your comments on this . Thanks.
The patent application for the 1990's test appears to require 1) a chemical extraction 2) the use of a thin layer gas chromatograph (the average ER does not have this equipment nor does it have people trained to run this equipment) 3) the reading of a flourescent spot following the use of the chromatograph. ERs & docs may have been scared away by the equipment and personnel requirements.
Uroerythrin is the previous analyte tested. I suspect that the trial run by APPY is similar to the previous trial data. If Uroerythrin didn't make it, perhaps there is not enough demand for appendicitis testing.
It could also be that whomever had the patent rights tried to sell the test to Abbott/JNJ/Roche..etc...and no one wanted to pay the royalties.
APPY will have to be smart to get this test to market. They have no presence in the hospital market, so my guess is they will have to push the test through a partner. The stock price is definitely ahead of itself with all the question-marks. A good pump.